TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET 14
1.4 LIMITATIONS 16
1.5 MARKETS COVERED 17
2 MARKET SEGMENTATION 20
2.1 MARKETS COVERED 20
2.2 GEOGRAPHICAL SCOPE 21
2.3 YEARS CONSIDERED FOR THE STUDY 21
2.4 CURRENCY AND PRICING 21
2.5 DBMR TRIPOD DATA VALIDATION MODEL 22
2.6 MULTIVARIATE MODELLING 25
2.7 MOLECULE LIFELINE CURVE 25
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 26
2.9 DBMR MARKET POSITION GRID 27
2.10 VENDOR SHARE ANALYSIS 29
2.11 MARKET TYPE OF END USER COVERAGE GRID 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHT 36
4.1 PORTERS FIVE FORCES 37
4.2 PESTEL ANALYSIS 38
4.3 CONTACT LIST OF MARKETING PERSONS INVOLVE IN PURCHASE OF ACTIVE PHARMACEUTICAL INGREDIENTS 39
4.4 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET 40
5 REGULATORY FRAMEWORK 41
5.1 OVERVIEW 41
5.2 CURRENT GOODS MANUFACTURING PRACTICES 41
5.3 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN VIETNAM 42
6 MARKET OVERVIEW 43
6.1 DRIVERS 45
6.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISEASE 45
6.1.2 INCREASE IN THE AGING POPULATION 45
6.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING 46
6.1.4 INCREASING DISEASE AWARENESS AND EDUCATION 47
6.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API) 47
6.2 RESTRAINTS 48
6.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS 48
6.2.2 HIGH MANUFACTURING COST 49
6.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API) 49
6.3 OPPORTUNITIES 50
6.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS 50
6.3.2 INCREASING HEALTHCARE EXPENDITURE 51
6.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) 51
6.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS 52
6.4 CHALLENGES 54
6.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19 54
6.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES 55
7 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC CLASS 56
7.1 OVERVIEW 57
7.2 ANTIBIOTIC 62
7.3 CARDIOVASCULAR 62
7.4 LIPID LOWERING DRUGS 62
7.5 INFECTIOUS DISEASE 63
7.6 ANESTHETIC 63
7.7 NSAIDS 63
7.8 ANALGESIC 64
7.9 ANTIVIRAL 64
7.10 DERMATOLOGY 65
7.11 ONCOLOGY 65
7.12 ENDOCRINOLOGY 65
7.13 UROLOGY 66
7.14 GASTROENTEROLOGY 66
7.15 OPHTHALMOLOGY 66
7.16 HORMONAL AGENTS 67
7.17 MUSCLE RELAXANT 67
7.18 PARKINSON 68
7.19 PSORIASIS 68
7.20 EPILEPTIC 68
7.21 IMMUNOLOGY 69
7.22 HEMATOLOGY 69
7.23 ANTINEOPLASTIC 69
7.24 IMMUNOSUPPRESSIVE AGENTS 70
7.25 OTHERS 70
8 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE 71
8.1 OVERVIEW 72
8.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT 75
8.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT 75
9 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER 76
9.1 OVERVIEW 77
9.2 CAPTIVE MANUFACTURERS 80
9.2.1 CAPTIVE INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT 80
9.2.2 CAPTIVE GENERIC ACTIVE PHARMACEUTICAL INGREDIENT 80
9.3 MERCHANT MANUFACTURERS 80
9.3.1 MERCHANT INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT 81
9.3.2 MERCHANT GENERIC ACTIVE PHARMACEUTICAL INGREDIENT 81
10 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS 82
10.1 OVERVIEW 83
10.2 CHEMICAL SYNTHETIC 86
10.2.1 SAXAGLIPTIN 87
10.2.2 ENOXAPARIN SODIUM 87
10.2.3 RUFINAMIDE 87
10.2.4 TAMOXIFEN 87
10.2.5 ARTEMISININ 87
10.2.6 LOSARTAN POTASSIUM 87
10.2.7 NAPROXEN 87
10.2.8 IBUPROFEN 87
10.2.9 ACETAMINOPHEN 87
10.2.10 SODIUM CHLORIDE 87
10.2.11 OTHERS 88
10.3 BIOTECH 88
10.3.1 MONOCLONAL ANTIBODIES 88
10.3.2 CYTOKINES 89
10.3.3 HORMONES & GROWTH FACTORS 89
10.3.4 BLOOD FACTORS 89
10.3.5 RECOMBINANT VACCINES 89
10.3.6 THERAPEUTIC ENZYMES BIOTECH 89
11 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY 90
11.1 OVERVIEW 91
11.2 TRADITIONAL POTENCY ACTIVE PHARMACEUTICAL INGREDIENT 94
11.3 HIGH POTENCY ACTIVE PHARMACEUTICAL INGREDIENT 94
12 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, TYPE OF DRUG 95
12.1 OVERVIEW 96
12.2 PRESCRIPTION DRUGS 99
12.3 OVER-THE-COUNTER DRUGS 99
13 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, MOLECULE 100
13.1 OVERVIEW 101
13.2 SMALL MOLECULE 104
13.3 LARGE MOLECULE 104
14 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, APPLICATION 105
14.1 OVERVIEW 106
14.2 CLINICAL 109
14.3 RESEARCH 109
15 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY END USER 110
15.1 OVERVIEW 111
15.2 PHARMACEUTICAL INDUSTRIES 114
15.2.1 LARGE 114
15.2.2 MEDIUM 114
15.2.3 SMALL 114
15.3 BIOTECHNOLOGY INDUSTRIES 115
15.3.1 LARGE 115
15.3.2 MEDIUM 115
15.3.3 SMALL 115
15.4 RESEARCH AND ACADEMIC INSTITUTES 116
15.5 OTHERS 116
16 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY DISTRIBUTION CHANNEL 117
16.1 OVERVIEW 118
16.2 DIRECT TENDERS 121
16.3 RETAIL SALES 121
16.4 OTHERS 122
17 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY LANDSCAPE 123
17.1 COMPANY SHARE ANALYSIS: VIETNAM 123
18 SWOT ANALYSIS 124
19 COMPANY PROFILE 125
19.1 PFIZER, INC. 125
19.1.1 COMPANY SNAPSHOT 125
19.1.2 REVENUE ANALYSIS 125
19.1.3 PRODUCT PORTFOLIO 126
19.1.4 RECENT DEVELOPMENTS 126
19.2 MEKOPHAR 128
19.2.1 COMPANY SNAPSHOT 128
19.2.2 RECENT FINANCIALS 128
19.2.3 PRODUCT PORTFOLIO 129
19.2.4 RECENT DEVELOPMENT 129
19.3 ASTRAZENECA 130
19.3.1 COMPANY SNAPSHOT 130
19.3.2 REVENUE ANALYSIS 130
19.3.3 PRODUCT PORTFOLIO 131
19.3.4 RECENT DEVELOPMENT 131
19.4 DIVIS LABORATORIES LIMITED 132
19.4.1 COMPANY SNAPSHOT 132
19.4.2 REVENUE ANALYSIS 132
19.4.3 PRODUCT PORTFOLIO 133
19.4.4 RECENT DEVELOPMENTS 133
19.5 SANOFI 135
19.5.1 COMPANY SNAPSHOT 135
19.5.2 REVENUE ANALYSIS 135
19.5.3 PRODUCT PORTFOLIO 136
19.5.4 RECENT DEVELOPMENTS 136
19.6 DR. REDDYS LABORATORY LTD. 137
19.6.1 COMPANY SNAPSHOT 137
19.6.2 RECENT FINANCIALS 137
19.6.3 PRODUCT PORTFOLIO 138
19.6.4 RECENT DEVELOPMENT 138
19.7 AUROBINDO PHARMA 139
19.7.1 COMPANY SNAPSHOT 139
19.7.2 REVENUE ANALYSIS 139
19.7.3 PRODUCT PORTFOLIO 140
19.7.4 RECENT DEVELOPMENT 140
19.8 BASF SE 141
19.8.1 COMPANY SNAPSHOT 141
19.8.2 RECENT FINANCIALS 141
19.8.3 PRODUCT PORTFOLIO 142
19.8.4 RECENT DEVELOPMENT 142
19.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH. 143
19.9.1 COMPANY SNAPSHOT 143
19.9.2 REVENUE ANALYSIS 143
19.9.3 PRODUCT PORTFOLIO 144
19.9.4 RECENT DEVELOPMENTS 144
19.10 GSK PLC 145
19.10.1 COMPANY SNAPSHOT 145
19.10.2 REVENUE FINANCIALS 145
19.10.3 PRODUCT PORTFOLIO 146
19.10.4 RECENT DEVELOPMENT 146
19.11 JUBILANT PHARMOVA LIMITED 147
19.11.1 COMPANY SNAPSHOT 147
19.11.2 REVENUE ANALYSIS 147
19.11.3 PRODUCT PORTFOLIO 148
19.11.4 RECENT DEVELOPMENT 148
19.12 LUPIN 149
19.12.1 COMPANY SNAPSHOT 149
19.12.2 REVENUE ANALYSIS 149
19.12.3 PRODUCT PORTFOLIO 150
19.12.4 RECENT DEVELOPMENTS 150
19.13 NOVO NORDISK A/S 152
19.13.1 COMPANY SNAPSHOT 152
19.13.2 REVENUE ANALYSIS 152
19.13.3 PRODUCT PORTFOLIO 153
19.13.4 RECENT DEVELOPMENT 153
19.14 SUN PHARMACEUTICAL INDUSTRIES LTD. 154
19.14.1 COMPANY SNAPSHOT 154
19.14.2 REVENUE ANALYSIS 154
19.14.3 PRODUCT PORTFOLIO 155
19.14.4 RECENT DEVELOPMENT 155
19.15 UNICHEM LABORATORIES 156
19.15.1 COMPANY SNAPSHOT 156
19.15.2 REVENUE ANALYSIS 156
19.15.3 PRODUCT PORTFOLIO 157
19.15.4 RECENT DEVELOPMENTS 157
20 QUESTIONNAIRE 159
21 RELATED REPORTS 164

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.